THC Temporarily Lowered Eye Pressure for Glaucoma While CBD Had No Effect or Raised It
In a small crossover trial of 6 glaucoma patients, sublingual THC (5 mg) significantly lowered eye pressure for 2 hours, while CBD (20 and 40 mg) did not reduce pressure and the higher CBD dose actually caused a transient increase.
Quick Facts
What This Study Found
Six patients with ocular hypertension or early primary open angle glaucoma received single sublingual doses of 5 mg THC, 20 mg CBD, 40 mg CBD, or placebo in a randomized, double-masked crossover design.
Two hours after THC administration, intraocular pressure (IOP) was significantly lower than after placebo (23.5 mmHg vs. 27.3 mmHg, P = 0.026). The effect was temporary, returning to baseline by 4 hours.
CBD at 20 mg did not reduce IOP at any time point. The higher CBD dose (40 mg) actually produced a transient elevation of IOP at 4 hours (from 23.2 to 25.9 mmHg, P = 0.028). One patient experienced a transient mild panic reaction after THC administration.
Key Numbers
6 patients. THC 5 mg: IOP reduced from 27.3 to 23.5 mmHg (P = 0.026). Effect lasted about 2 hours. CBD 20 mg: no effect. CBD 40 mg: transient IOP increase at 4 hours (P = 0.028). 1 patient had mild panic reaction with THC.
How They Did This
Randomized, double-masked, placebo-controlled, 4-way crossover study at a single center. Six patients received sublingual doses of 5 mg THC, 20 mg CBD, 40 mg CBD, or placebo. IOP measured as primary outcome. Visual acuity, vital signs, and psychotropic effects monitored.
Why This Research Matters
This study clarified that while THC can lower eye pressure, its effect is brief (about 2 hours). More importantly, it showed CBD does not share this property and may actually raise eye pressure at higher doses, cautioning against assuming all cannabinoids help with glaucoma.
The Bigger Picture
The finding that CBD may increase eye pressure is clinically important given the growing popularity of CBD products. Glaucoma patients using CBD under the assumption it will help their condition might actually be worsening their eye pressure, highlighting the need for cannabinoid-specific research.
What This Study Doesn't Tell Us
Very small sample (6 patients). Single-dose study cannot assess tolerance or sustained effects. The crossover design with only one dose level per cannabinoid limits dose-response analysis. Sublingual delivery may not achieve optimal bioavailability.
Questions This Raises
- ?Would sustained THC dosing maintain the IOP-lowering effect or would tolerance develop?
- ?Why does CBD appear to raise eye pressure?
- ?Is there a THC delivery method that could maintain IOP reduction without frequent dosing?
Trust & Context
- Key Stat:
- THC lowered eye pressure for 2 hours; high-dose CBD actually raised it transiently
- Evidence Grade:
- Randomized, double-masked, placebo-controlled crossover study. Good design but only 6 patients, limiting statistical power and generalizability.
- Study Age:
- Published in 2006. THC's brief IOP-lowering effect and the need for frequent dosing remain obstacles to using cannabinoids for glaucoma treatment.
- Original Title:
- Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.
- Published In:
- Journal of glaucoma, 15(5), 349-53 (2006)
- Authors:
- Tomida, Ileana, Azuara-Blanco, Augusto, House, Heather(3), Flint, Maggie, Pertwee, Roger G, Robson, Philip J
- Database ID:
- RTHC-00248
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Does cannabis help with glaucoma?
THC temporarily lowered eye pressure in this study, but the effect lasted only about 2 hours, requiring impractical dosing frequency. CBD did not help and may actually raise eye pressure at higher doses. Most ophthalmologists do not recommend cannabis for glaucoma management.
Can CBD help with glaucoma?
No. In this study, CBD at 20 mg had no effect on eye pressure, and 40 mg actually caused a transient increase. This is an important caution for glaucoma patients using CBD products.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00248APA
Tomida, Ileana; Azuara-Blanco, Augusto; House, Heather; Flint, Maggie; Pertwee, Roger G; Robson, Philip J. (2006). Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.. Journal of glaucoma, 15(5), 349-53.
MLA
Tomida, Ileana, et al. "Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.." Journal of glaucoma, 2006.
RethinkTHC
RethinkTHC Research Database. "Effect of sublingual application of cannabinoids on intraocu..." RTHC-00248. Retrieved from https://rethinkthc.com/research/tomida-2006-effect-of-sublingual-application
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.